The Use and Safety of a Novel Haemostatic Spray in the Endoscopic Management of Acute Nonvariceal Upper Gastrointestinal Bleeding in Children

Thomson, Mike; Urs, Arun; Narula, Priya; Rao, Prithviraj; Belsha, Dalia

doi:10.1097/mpg.0000000000001967

Cited by 12 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the fourth cohort study selected, Thomson et al 40 evaluated pediatric patients with non-variceal UGIB, comparing outcomes in a group of 17 patients with ages ranging from 1 day to 16 years who were treated with TC-325 with those reported for a historical cohort of 29 children previously treated with conventional endoscopic techniques. Initial hemostasis was achieved in 100 % of the patients in both groups.…”

Section: Resultsmentioning

confidence: 99%

Use of hemostatic powder in treatment of upper gastrointestinal bleeding: a systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

Background and study aims TC-325 is a novel mineral hemostatic powder that creates a mechanical barrier by absorbing blood components and promoting clotting. Recently approved for use in humans, it has shown promise for treatment of upper gastrointestinal bleeding (UGIB). However, because there have been no large studies of TC-325, its true efficacy and safety profile remain unknown. We performed a systematic review and meta-analysis to determine the safety and efficacy of TC-325 in treating UGIB, based on rates of initial hemostasis, rebleeding, and adverse events (AEs). Methods We searched the MEDLINE/PubMed, EMBASE, CENTRAL, Latin-American and Caribbean Health Sciences Literature databases, as well as the gray literature, to identify articles describing use of TC-325 up to October 2018. Primary outcomes were initial hemostasis and rebleeding. AEs were described as a secondary outcome. Risk of bias was assessed with international scores. Results We identified 2077 records after removal of duplicates. We included 50 studies, involving a collective total of 1445 patients, in the quantitative synthesis. Primary hemostasis and rebleeding rates were 90.7 % and 26.1 %, respectively. Subgroup analyses showed similar results. Only eight AEs were reported. Conclusions TC-325 appears to be a safe, effective treatment for UGIB. The overall rate of initial hemostasis after TC-325 use is high, regardless of etiology of bleeding or whether TC-325 is used as a primary or rescue therapy. Although it is also associated with high rebleeding rates, rates of AEs and equipment failure after TC-325 use are extremely low.

show abstract

Section: Resultsmentioning

confidence: 99%

Use of hemostatic powder in treatment of upper gastrointestinal bleeding: a systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, these drugs, due to their ability to cover vast areas with multiple bleeding points, are appropriate choices for treating bleeding from hemorrhagic gastritis, gastric artery ecstasy, mucosal damage caused by radiotherapy, and hemorrhage associated with malignancy. 18 In this study, a 3-month follow-up survey did not show any specific complication due to drug use. In an animal study, all mice and rabbits treated with Hemostasis powder® solution were killed and all of their end organs as well as the stomach were sent for pathological examination to determine the probability of toxicity of the solution, which showed no pathological lesions in these organs.…”

Section: Discussionmentioning

confidence: 44%

“…17 Another benefit is the lack of need for injecting needle that reduces the risk of damage to other tissues (due to needle-stick contact with the mucosa), which can worsen bleeding and even lead to mucus perforation, if occurs. 18…”

Section: Discussionmentioning

confidence: 99%

The Effect of Hemostasis Powder® on Treatment of Bleeding from Benign Ulcers of Upper Gastrointestinal Tract; A Pilot Study

Vafaeimanesh

Rakhshandeh

Pourakbar

et al. 2019

Middle East J Dig Dis

View full text Add to dashboard Cite

BACKGROUND Gastrointestinal (GI) bleeding is one of the most prevalent internal medical emergencies. Despite using several methods of treatment, effective treatment cannot be achieved in some patients. Hemostasis powder® is a mineral-herbal product. This emulsion was able to coagulate blood in, in vitro studies and also was effective in the treatment of mucosal and cutaneous bleeding in animal studies, without any toxicity. We decided to compare its effect on the treatment of human GI bleeding with the other common method for treatment of GI bleeding "argon plasma coagulation plus epinephrine injection" in a pilot randomized clinical trial. METHODS The patients with GI bleeding who were admitted to the emergency wards of Ghaem and Imam-Reza Hospitals in Mashhad were randomized to treatment with Hemostasis powder® or "argon plasma coagulation plus epinephrine injection" method, with randomized doctors, after complete testimonial sheet. The patients underwent re-endoscopy to evaluate the ulcers 3 days later, and were under observation for 3 months. After achieving the number of patients that was planned (20 patients), all data were entered to SPSS software version 20 and were analyzed with parametric and non-parametric tests. RESULTS The treatment success was 95% in both groups. There was no complication after treatment of GI bleeding in the two groups after 3 months. No rebreeding was reported in Hemostasis powder® group but 10 % was reported in "argon plasma coagulation plus epinephrine injection" group. CONCLUSION It seems that if the successful results occur in the future complimentary studies, Hemostasis powder® can be used as a new, effective, available, and inexpensive measure in the treatment of GI bleeding and also in the GI bleedings that cannot be treated with common available methods.

show abstract

“…Indeed 19% admitted that those interventions were beyond the technical capability of any of their staff. Only just over a half of the centers had an out-of-hours call service, of which 69% was covered by pediatric surgeons, who were also often unfamiliar with most of the techniques required (17). In this regard, a technique which is easily accessible even for less-experienced endoscopists is extremely valuable.…”

Section: Topical Hemostatic Endoscopic Approaches For Gi Bleedingmentioning

confidence: 99%

Therapeutic Upper Gastrointestinal Endoscopy in Pediatric Gastroenterology

2022

Self Cite

View full text Add to dashboard Cite

show abstract

The Use and Safety of a Novel Haemostatic Spray in the Endoscopic Management of Acute Nonvariceal Upper Gastrointestinal Bleeding in Children

Abstract: This paediatric series suggests that monotherapy with haemostatic spray is as effective as conventional approaches in the management of AUGIB.

Cited by 12 publications

References 16 publications

Use of hemostatic powder in treatment of upper gastrointestinal bleeding: a systematic review and meta-analysis

Use of hemostatic powder in treatment of upper gastrointestinal bleeding: a systematic review and meta-analysis

The Effect of Hemostasis Powder® on Treatment of Bleeding from Benign Ulcers of Upper Gastrointestinal Tract; A Pilot Study

Therapeutic Upper Gastrointestinal Endoscopy in Pediatric Gastroenterology

Contact Info

Product

Resources

About